Hello Atlas Venture Partner - Neurology - Oncology

Welcome to Atlas Ventures Partner Portal. Here you will have access to all the newest information and resources catering to your specific needs and interests. Sign in below for instant access.

Sign In Here

Atlas Venture logo
Latest Insights/Resources
 
 
 
 

Drive Your Oncology Research

Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized tumor models. Charles River is driving oncology drug discovery across a range of modalities including small molecules, immune therapies, biologics, cell therapies.

What can we accomplish together?


The Impact of the Tumor Microenvironment | Rhiannon Jenkinson, Director of Science at Charles River

In this video, Rhiannon Jenkinson discusses the impact of the Tumor Microenvironment on immune-oncology drug development, and how the immune system can be harnessed to fight cancer.


In Vitro Cytotoxicity Testing of CAR-T Cells | Sanne Demandt, Group Leader for Biology at Charles River

In this video, Sanne Demandt discusses in vitro cytotoxicity testing of CAR T cells.


In Vivo Cancer Models:

  •     Cell line-derived xenograft models in mice and rats
  •     Patient-derived xenograft (PDX) models
  •     Syngeneic models
  •     Humanized mice tumor models
  •     Orthotopic models
  •     Single mouse trials
  •     Cachexia models
  •     Graft versus Host models
  •     Immuno-oncology pharmacodynamic models

Combining these cancer models with appropriate translational tools like ELISpot, flow cytometry, imaging, gene expression analysis, and tumor microdialysis, you can develop the most efficient, relevant study design and screening method to identify promising compounds and optimize lead candidates.


Microdialysis: A Novel Tool to Sample the Tumor Microenvironment

composition of tumor microenvironment

Learn how microdialysis, a uniquely sensitive method for sampling and quantifying multiple immunomodulators and oncometabolites, elucidates the mechanisms by which oncology therapies modulate the TME.

Watch the Webinar

Collaborative Learning

Drive Your Oncology Research

Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized tumor models. Charles River is driving oncology drug discovery across a range of modalities including small molecules, immune therapies, biologics, cell therapies.


The Impact of the Tumor Microenvironment | Rhiannon Jenkinson, Director of Science at Charles River

In this video, Rhiannon Jenkinson discusses the impact of the Tumor Microenvironment on immune-oncology drug development, and how the immune system can be harnessed to fight cancer.


In Vitro Cytotoxicity Testing of CAR-T Cells | Sanne Demandt, Group Leader for Biology at Charles River Leiden

In this video, Sanne Demandt discusses in vitro cytotoxicity testing of CAR T cells.


In Vivo Cancer Models:

 •   Cell line-derived xenograft models in mice and rats
 •   Patient-derived xenograft (PDX) models
 •   Syngeneic models
 •   Humanized mice tumor models
 •   Orthotopic models
 •   Single mouse trials
 •   Cachexia models
 •   Graft versus Host models
 •   Immuno-oncology pharmacodynamic models

Combining these cancer models with appropriate translational tools like ELISpot, flow cytometry, imaging, gene expression analysis, and tumor microdialysis, you can develop the most efficient, relevant study design and screening method to identify promising compounds and optimize lead candidates.


Microdialysis: A Novel Tool to Sample the Tumor Microenvironment

composition of tumor microenvironment

Learn how microdialysis, a uniquely sensitive method for sampling and quantifying multiple immunomodulators and oncometabolites, elucidates the mechanisms by which oncology therapies modulate the TME.

Watch the Webinar

Quick Links

Need more information on a specific therapeutic area or technology? Check out these resources…

Oncology

 •   Charles River Oncology
 •   Oncology Analysis Methods & Endpoints
 •   Oncology Models
 •   Oncology Assays
 •   Oncology & Immuno-Oncology Studies

Neuroscience

 •   Neuroscience Microsite
 •   Neuroscience Methods & Endpoints
 •   Neuroscience Studies

Platforms and Technologies

 •   Hit Finding eGuide for Hit Identification
 •   Antibody Library Screening for Antibody Discovery
 •   Screening and Profiling Assays

Immunology/Inflammation

 •   Immunology Microsite
 •   Inflammation & Autoimmune Disease Studies
 •   In Vitro Immunology

Other

 •   Cardiovascular/Metabolic Disease Studies
 •   Musculoskeletal Disease Studies
 •   Ocular Disease Studies

Newsletters

Catch up on our latest news collections…

 •   Q2 2020: New Regulations for COVID-19 Vaccine Development

 •   Q1 2020: Expanding Digital Resources To Support You

 •   Q4 2019: See How This Little Girl Changed Drug Development Forever

 •   Q3 2019: A Collaborative Breakthrough for Cardiovascular Patients